QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2026-07-03
Target enrollment:
Participant gender:
Summary
This is a single-arm, single-center, interventional, dose-escalation clinical study designed
to evaluate the safety and tolerability of QH103 Cell Injection in the treatment of patients
with relapsed/refractory B-cell acute lymphoblastic leukemia.